Kira Pharmaceuticals Shares Encouraging KP104 Phase 2 PNH Trial Outcomes at 2024 EHA Congress, Highlighting Sustained Safety and Effectiveness.

A Biologics License Application for subcutaneous amivantamab was submitted to the U.S. FDA for people with non-small cell lung cancer with EGFR mutations.

The SKYLINE trial was a multicenter, randomized, and double-blind Phase 3 study that assessed the combination of soticlestat (TAK-935) with standard care against a placebo with standard care in patients suffering from refractory Dravet syndrome.

Nurix Therapeutics Reports Successful Outcomes from NX-5948 Trial in Relapsed Refractory CLL Patients at EHA2024 Congress.

Electra Therapeutics Reveals New Clinical Findings at EHA2024 from Active Phase 1b Trial of ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH).

Cabaletta Bio Releases Favorable Early Clinical Results from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Studies of CABA-201.

Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.

Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.

FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.

Celltrion presents encouraging phase III data for CT-P47, a biosimilar of RoActemra® (tocilizumab), in RA patients at EULAR 2024.

ELREXFIO™ Demonstrates Over Two-Year Median Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma.

Vertex Showcases Promising Long-Term Results for CASGEVY™ (exagamglogene autotemcel) at the 2024 EHA Congress.